Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins

Contraception

Volumn 74, Issue 4, 2006, Pages 293-296

  White, Terry ^a   Özel, Begüm ^a   Jain, John K ^a   Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

C reactive protein; Ethinyl estradiol; Oral contraceptives; Serum binding globulins; Transdermal contraception

Indexed keywords

C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; LIVER PROTEIN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; THYROXINE BINDING GLOBULIN; TRANSCORTIN;

ADULT; ARTICLE; CONTRACEPTION; DRUG EFFECT; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; ORAL CONTRACEPTION; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, CUTANEOUS; ADULT; BLOOD PROTEINS; BODY MASS INDEX; C-REACTIVE PROTEIN; CONTRACEPTIVE AGENTS; CONTRACEPTIVES, ORAL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; LIVER; RECEPTORS, CELL SURFACE; SERPINS; SEX HORMONE-BINDING GLOBULIN; THYROXINE-BINDING PROTEINS; TRANSCORTIN;

EID: 33748542627     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.04.005     Document Type: Article

References (19)

1. Juchem M., Pollow E., Elger W., Hoffman G., and Mobus V. Receptor binding of norgestimate - a new orally active synthetic progestational compound. Contraception 47 (1993) 283-294
2. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 3 (2002) 211-224
3. Moore D.E., Kawagoe S., Davajan V., Nakamura R.M., and Mishell D.R. An in vivo system in man for quantification of estrogenicity: II. Pharmacologic changes in binding capacity of corticosteroid-binding globulin induced by conjugated estrogens, mestranol, and ethinyl estradiol. Am J Obstet Gynecol 130 (1978) 482-486
4. Wiegratz I., Kutschera E., Lee J.H., et al. Effect of four different oral contraceptives on various sex hormones and serum binding globulins. Contraception 67 (2003) 25-32
5. Thorneycroft I.H., Stanczyk F.Z., Bradshaw K.D., Ballagh S.A., Nichols M., and Weber M.E. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 60 (1999) 255-262
6. Coenen C.M.H., Thomas C.M.G., Borm G.F., and Rolland R. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. Int J Fertil 40 Suppl 2 (1995) 92-97
7. Jung-Hoffmann C., Storch A., and Kuhl H. Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG, and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel. Horm Res 38 (1992) 184-189
8. Van der Vange N., Blankenstein M.A., Kloosterboer H.J., Haspels A.A., and Thijssen J.H.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 41 (1990) 345-352
9. Stanczyk F.Z., Hiroi M., Goebelsmann U., Brenner P.F., Lumkin M.E., and Mishell Jr. D.R. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. Contraception 12 (1975) 279-298
10. Price T.M., Dupuis R.E., Carr B.R., Stanczyk F.Z., Lobo R.A., and Droegemueller W. Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol 168 (1993) 1400-1406
11. White T., Jain J.K., and Stanczyk F.Z. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 192 (2005) 2055-2059
12. Wiegratz I., Jung-Hoffman C., and Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 51 (1995) 341-346
13. Hammond G.L., Langley M.S., Robinson P.A., Nummi S., and Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 42 (1984) 44-51
14. Sobbrio G.A., Granata A., Granese D., et al. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen. Clin Exp Obstet Gynecol 18 (1991) 43-45
15. Ain K.B., Mori Y., and Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 65 (1987) 689-696
16. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
17. Van Rooijen M., Hansson L.O., Frostegard J., Silveira A., Hamsten A., and Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 4 (2006) 77-82
18. Abrams L.S., Skee D., Natarajan J., and Wong F.A. Pharmacokinetic overview of Ortho Evra™/Evra™. Fertil Steril 77 Suppl 2 (2002) S3-S12
19. Van den Heuvel M.W., Van Bragt A.J.M., Alnabawy A.K.M., and Kaptein M.C.J. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 (2005) 168-174